Market Closed -
TEL AVIV STOCK EXCHANGE
10:24:14 2024-06-27 EDT
|
5-day change
|
1st Jan Change
|
238.4
ILa
|
+1.02%
|
|
+1.88%
|
-20.48%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
39.24
|
170.9
|
71.25
|
26.24
|
41.96
|
32.15
|
-
|
-
|
Enterprise Value (EV)
1 |
39.24
|
170.9
|
71.25
|
26.24
|
41.96
|
32.15
|
32.15
|
32.15
|
P/E ratio
|
-7.51
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
164
x
|
76.6
x
|
15.7
x
|
7.44
x
|
2.14
x
|
1.24
x
|
0.68
x
|
EV / Revenue
|
-
|
164
x
|
76.6
x
|
15.7
x
|
7.44
x
|
2.14
x
|
1.24
x
|
0.68
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-1.91
x
|
-2.02
x
|
-2.19
x
|
-7.15
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
25,754
|
35,575
|
41,164
|
41,216
|
50,550
|
50,659
|
-
|
-
|
Reference price
2 |
5.256
|
15.44
|
5.375
|
2.235
|
2.998
|
2.384
|
2.384
|
2.384
|
Announcement Date
|
20-03-04
|
21-03-03
|
22-03-10
|
23-03-09
|
24-03-07
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
1.04
|
0.93
|
1.675
|
5.64
|
14.99
|
25.85
|
47.28
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-22.02
|
-15.92
|
-14.69
|
-4.496
|
EBIT
1 |
-
|
-24.81
|
-30.95
|
-26.94
|
-26.51
|
-21.18
|
-19.94
|
-10.62
|
Operating Margin
|
-
|
-2,385.96%
|
-3,328.28%
|
-1,608.42%
|
-470%
|
-141.27%
|
-77.13%
|
-22.47%
|
Earnings before Tax (EBT)
1 |
-
|
-26.17
|
-30.43
|
-29.75
|
-25.99
|
-20.41
|
-19.69
|
-10.5
|
Net income
1 |
-18.11
|
-23.37
|
-27.79
|
-26.64
|
-23.88
|
-22.05
|
-19.7
|
-10.18
|
Net margin
|
-
|
-2,247.5%
|
-2,988.49%
|
-1,590.33%
|
-423.39%
|
-147.09%
|
-76.19%
|
-21.53%
|
EPS
|
-0.7000
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-03-04
|
21-03-03
|
22-03-10
|
23-03-09
|
24-03-07
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
0.151
|
0.311
|
0.237
|
0.312
|
0.466
|
0.66
|
0.641
|
0.654
|
3.767
|
0.578
|
4.19
|
0.8
|
4.2
|
5.8
|
2.5
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-5.737
|
-6.453
|
-2.977
|
-6.852
|
-3.415
|
-5.905
|
-4.335
|
-3.325
|
-
|
EBIT
1 |
-8.556
|
-8.692
|
-8.055
|
-8.007
|
-7.097
|
-3.782
|
-6.796
|
-7.901
|
-4.183
|
-7.628
|
-4.086
|
-7.08
|
-5.51
|
-4.5
|
-
|
Operating Margin
|
-5,666.23%
|
-2,794.86%
|
-3,398.73%
|
-2,566.35%
|
-1,522.96%
|
-573.03%
|
-1,060.22%
|
-1,208.1%
|
-111.04%
|
-1,319.72%
|
-97.52%
|
-885%
|
-131.19%
|
-77.59%
|
-
|
Earnings before Tax (EBT)
1 |
-8.335
|
-8.09
|
-9.104
|
-9.716
|
-7.158
|
-3.776
|
-7.026
|
-7.757
|
-3.863
|
-7.341
|
-3.845
|
-6.88
|
-5.335
|
-4.35
|
-
|
Net income
1 |
-7.61
|
-7.371
|
-9.106
|
-8.821
|
-6.544
|
-2.998
|
-6.271
|
-7.023
|
-3.984
|
-6.601
|
-3.863
|
-6.192
|
-4.802
|
-3.915
|
-
|
Net margin
|
-5,039.74%
|
-2,370.1%
|
-3,842.19%
|
-2,827.24%
|
-1,404.29%
|
-454.24%
|
-978.32%
|
-1,073.85%
|
-105.76%
|
-1,142.04%
|
-92.2%
|
-774%
|
-114.33%
|
-67.5%
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-17
|
22-03-10
|
22-05-26
|
22-08-31
|
22-11-17
|
23-03-09
|
23-05-18
|
23-08-17
|
23-11-15
|
24-03-07
|
24-05-23
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
1.17
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
69.91%
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-03-04
|
21-03-03
|
22-03-10
|
23-03-09
|
24-03-07
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -20.48% | 32.08M | | +38.65% | 39.36B | | -8.62% | 38.52B | | +26.95% | 30.74B | | +10.74% | 25.92B | | -13.50% | 26.03B | | +44.87% | 14.13B | | +34.36% | 12.73B | | -7.14% | 11.29B | | -12.61% | 10.64B |
Other Biotechnology & Medical Research
|